EyePoint Stock: Key Player In The Long-Acting Wet AMD Space (NASDAQ:EYPT)
zoranm Shares of ocular disease upstart EyePoint Pharmaceuticals (NASDAQ:EYPT) have lost over 25% of their value over the past 3 years. So far in 2022, they are in the red by about 15%. Unintentionally, the […]
